Work

610P BXCL701 - 1st-in-class oral activator of systemic innate immunity-combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase II results

Year: 2021

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1123

Authors: P. Monk, J. Zhang, D. Costin, D.P. Petrylak, S.T. Tagawa, L.I. Karsh, X. Zhu, M. Linch, R. Jones, P. Borderies, V. O'Neill, R.R. Aggarwal

Institutions: The Ohio State University, Moffitt Cancer Center, White Plains Hospital, Yale University, NewYork–Presbyterian Hospital, Weill Cornell Medical Center, The Urology Center of Colorado, Northwell Health, University College Hospital, NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre, BioXcel Therapeutics, Inc. (United States), University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3203842859

FWCI: 0.647

Cites:

Cited by: 4

Related to: 10